Diversity, Equity, and Inclusion in Clinical Trials

Grace Keegan; Angelena Crown; Kathie-Ann Joseph

doi:10.1016/j.soc.2022.08.005

Diversity, Equity, and Inclusion in Clinical Trials

Surg Oncol Clin N Am. 2023 Jan;32(1):221-232. doi: 10.1016/j.soc.2022.08.005. Epub 2022 Nov 3.

Authors

Grace Keegan¹, Angelena Crown², Kathie-Ann Joseph³

Affiliations

¹ Keegan-University of Chicago, Pritzker School of Medicine, 924 E. 57th Street, Chicago, IL 60637, USA.
² Breast Surgery, True Family Women's Cancer Center, Swedish Cancer Institute, Seattle, WA, USA.
³ Department of Surgery, New York University Grossman School of Medicine, NYC Health and Hospitals/Bellevue, New York, NY, USA; NYU Langone Health's Institute for Excellence in Health Equity, 180 Madison Avenue, New York, NY, USA. Electronic address: Kathie-Ann.Joseph@nyulangone.org.

PMID: 36410919
DOI: 10.1016/j.soc.2022.08.005

Abstract

Minority groups are vastly underrepresented in clinical trial participants and leadership. Because these studies provide innovative and revolutionary treatment options to patients with cancer and have the potential to extend survival, it is imperative that public and private stakeholders, as well as hospital and clinical trial leadership, prioritize equity and inclusion of diverse populations in clinical trial development and recruitment strategies. Achieving equity in clinical trials could be an important step in reducing the overall cancer burden and mortality disparities in vulnerable populations.

Keywords: Clinical trials; Diversity; Equity; Inclusion; Minority groups; Vulnerable populations.

Publication types

Review